Show simple item record

dc.contributor.authorPettinger, C
dc.contributor.authorLivings, C
dc.contributor.authorGrochot, R
dc.contributor.authorFurness, A
dc.contributor.authorLopez, J
dc.coverage.spatialEngland
dc.date.accessioned2023-01-10T13:48:49Z
dc.date.available2023-01-10T13:48:49Z
dc.date.issued2022-12-01
dc.identifierjitc-2022-006073
dc.identifier.citationJournal for ImmunoTherapy of Cancer, 2022, 10 (12), pp. e006073 - e006073
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5649
dc.identifier.eissn2051-1426
dc.identifier.eissn2051-1426
dc.identifier.doi10.1136/jitc-2022-006073
dc.description.abstractImmune cell engager therapeutic strategies using bioengineered molecules to redirect immune cells into tumor are starting to demonstrate promising clinical activity in multiple early phase trials across numerous targets and a range of solid tumor types. These therapies, however, carry the risk of exaggerated cytokine-mediated on-target off-tumor adverse events that require highly specialized inpatient facilities. We report here the Royal Marsden experience of treating patients with advanced solid tumors on early phase immune engager clinical trials in a dedicated inpatient facility, focusing specifically on patterns of cytokine-mediated toxicity seen and proposing a risk-mitigation algorithm for the safe, feasible and scalable delivery of these therapies.
dc.format.extente006073 - e006073
dc.languageeng
dc.language.isoeng
dc.publisherBMJ PUBLISHING GROUP
dc.relation.ispartofJournal for ImmunoTherapy of Cancer
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0
dc.subjectClinical Trials as Topic
dc.subjectImmunotherapy
dc.subjectHumans
dc.subjectImmunotherapy
dc.subjectNeoplasms
dc.subjectCytokines
dc.subjectHealth Services
dc.title'You give me fever!': are health services ready for immune cell engager therapy in advanced solid malignancies?
dc.typeJournal Article
dcterms.dateAccepted2022-12-07
dc.date.updated2023-01-10T12:39:56Z
rioxxterms.versionVoR
rioxxterms.versionofrecord10.1136/jitc-2022-006073
rioxxterms.licenseref.startdate2022-12-01
rioxxterms.typeJournal Article/Review
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/36564127
pubs.issue12
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR/ImmNet
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Early Phase Drug Development
pubs.publication-statusPublished
pubs.publisher-urlhttp://dx.doi.org/10.1136/jitc-2022-006073
pubs.volume10
icr.researchteamSkin Unit
icr.researchteamEarly Phase Drug Develop
dc.contributor.icrauthorFurness, Andrew
icr.provenanceDeposited by Ms Hilary Dent (impersonating Dr Juanita Lopez) on 2023-01-10. Deposit type is initial. No. of files: 1. Files: Pettinger_final for Symplectic.pdf
icr.provenanceDeposited by Mr Arek Surman (impersonating Dr Juanita Lopez) on 2023-01-10. Deposit type is subsequent. No. of files: 1. Files: e006073.full.pdf


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc/4.0